Compass Pathways · COMP360
Compass Pathways has been sending its application for FDA approval of COMP360, a psilocybin treatment for depression that hasn't responded to other treatments, in pieces, and says the last piece lands in late 2026. This market asks whether it finishes by December 31.
Price history
Full marketThe FDA accepts it for review
Usually about 60 days after filing.
The FDA decides
Usually 6–10 months after it accepts the filing.
Recent activity
| YES price | Shares | Value | Age |
|---|---|---|---|
| 54¢ | 10 | $5.40 | 23m |
| 59¢ | 16.29 | $9.61 | 25h |
| 57¢ | 6.94 | $3.96 | 11d |
| 61¢ | 17 | $10.37 | 11d |
| 62¢ | 17.05 | $10.57 | 11d |
The study reports that home-collected electrophysiology biomarkers can track depression recovery during deep brain stimulation, a potentially meaningful advance for biomarker-guided neuromodulation and psychiatric treatment optimization.
This preprint reports biomarker findings on white matter microstructure and later transition to psychosis in clinical high-risk individuals, which is scientifically relevant but not an immediate company-specific catalyst.
Compass Pathways said it will continue pursuing FDA submission despite the agency requesting another trial, keeping a key regulatory catalyst and approval timeline in focus.
Lucent